I'm intrigued that you seem to dismiss the rationale behind the interest of Novartis in finding a solution for ARDS. The primary cause of death in diseases like Influenza, and I suppose, still, COVID19. Do you not think that Novartis has significant expertise in pharmaeconomics, perhaps superior to your personal opinion. I suspect Novartis will have consulted the databases and done their sums.
And obviously they will have great interest in seeing what the data has to say from the COVID19 / ARDS trial, from the beginning to the end.
Then there are other issues like vascular dysfunction and long Covid.
MSB Trading 2021 - paradigm shift, page-121
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.015(1.40%) |
Mkt cap ! $1.238B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.12 | $1.08 | $11.51M | 10.52M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17804 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 230637 | 5 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.015 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.12 | $1.08 | 1937390 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| MSB (ASX) Chart |